Global Angina Pectoris Drugs Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 3.5% during forecast period.

Global Angina Pectoris Drugs Market Overview:

Angina Pectoris refers to the chest pain or discomfort caused due to coronary heart disease. It happens when the heart muscle does not receive enough oxygen or when one or more of the heart's arteries is narrowed or blocked, a condition known as ischemia.
Global Angina Pectoris Drugs Market Dynamics:

Increasing cases of Angina pectoris and other coronary heart diseases is the major driving factor for the market growth.

The rising burden of lifestyle diseases has a direct effect on the socio-economic aspects of nations around the world, necessitating immediate action to control them. As a result, the market for angina pectoris therapeutics is primarily driven by the rising prevalence of lifestyle diseases. Approximately, 9.8 million people in the United States are affected by angina pectoris each year and up to 500,000 new cases are diagnosed each year. Furthermore, the ease of availability of therapeutic drugs for angina pectoris, the development of new drugs, and increasing awareness about various cardiovascular disorders are expected to propel the market growth over the forecast period. Ongoing development of new therapies for the treatment of angina is expected to provide potential growth opportunities for the market growth. Other major drivers for the angina market are the aging global population, enhanced survival after surgery, and the increasing prevalence of obesity,

diabetes, and hypertension. Technological advances in personalized cardiovascular medicine, as well as the enhancement of innovative drug delivery systems, are other driving forces. Chronic stable angina pectoris affects 2–4% of the population in Western countries, states The British Journal of Cardiology, and is linked to an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1–2% and 3%, respectively.

However, factors such as low per capita healthcare spending and high cost for surgical procedures like coronary bypass surgery are expected to limit market growth over the forecast period. The overall cumulative cost of coronary bypass surgery was calculated to be USD 7,992 in a report published in the Brazilian Journal of Cardiovascular Surgery in 2017. Also, the increased use of minimally invasive surgeries may hamper the market growth for Angina Pectoris Drugs.

The report has profiled twenty two key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Angina Pectoris Drugs Market Segment Analysis:

The Global Angina Pectoris Drugs Market is segmented on the basis of Therapeutic Class, Type and End-Users.

Based on Therapeutic Class, the Beta Blockers segment is anticipated to account for the largest market share during the forecast period. Beta-blockers function by blocking the effects of the adrenaline-like hormone epinephrine. The heart beats more steadily and with less intensity as a result, lowering blood pressure. Beta-blockers also aid in the relaxation and opening of blood vessels, which improves blood flow and thereby reduces or prevents angina. With main patent expirations affecting GlaxoSmithKline's Coreg and AstraZeneca's Toprol, the Beta-Blocker sector is now primarily generic.

Global Angina Pectoris Drugs Market

To know about the Research Methodology :- Request Free Sample Report
Global Angina Pectoris Drugs Market Regional Insights:

Global Angina Pectoris Drugs Market

North America is expected to dominate the global market.

High Prevalence of coronary heart diseases due to sedentary lifestyle, increasing obese population and well-established healthcare infrastructure is the primary factor aiding the market growth in the region. Angina Pectoris affects about 9 million people in the United States and their treatment can be difficult. The U.S. held a prominent share of 33% in 2019. Increased adoption of therapeutics and ease of availability of drugs boost the market growth. Drugs like Dantonic (T89), which is a botanical medicine that combines extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule shape is the approved drug, states the US National Institutes of Health. These drugs are currently approved for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease-related disorders in 26 countries outside of the United States.

Asia Pacific is expected to grow at a significant rate during forecast period.

Because of the increasing prevalence of angina pectoris, high awareness of cardiovascular disorders, and improving healthcare infrastructure, Asia Pacific is expected to expand at a significant rate. Furthermore, the region's growth is expected to be fuelled by the presence of a large target population and significant unmet clinical needs.

The report also helps in understanding Global Angina Pectoris Drugs Market dynamics, structure by analyzing the market segments and project the Global Angina Pectoris Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Angina Pectoris Drugs Market make the report investor’s guide.
Global Angina Pectoris Drugs Market, Key Developments:

• Lupin Pharmaceuticals launched a drug named Ranolazine for the treatment of chronic angina in US, in February 2019.
Global Angina Pectoris Drugs Market Scope: Inquire before buying

Global Angina Pectoris Drugs Market
Global Angina Pectoris Drugs Market, By Region:

• North America
• Europe
• South America
Global Angina Pectoris Drugs Market, Key players:

• Sanofi
• Gilead
• AstraZeneca
• Pfizer
• Eli Lilly & Company
• Amgen
• GlaxoSmithKline
• Axus Cardium Pharmaceuticals
• LegoChem Biosciences
• Lee’s Pharmaceutical Holdings
• Milestone Pharmaceuticals
• Juventas Therapeutics
• ViroMed
• Kuhnil Pharmaceutical
• Johnson & Johnson
• Novartis AG
• Bristol-Myers Squibb Company
• Abbott
• Bayer AG
• Orion Corporation
• Merck & Co. Inc.
• Cardiorentis AG.

For More Information Visit @:
 This Report Is Submitted By : Maximize Market Research Company    
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:    
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors